Our vision
We are driven by a conviction: the only scientific research that matters is the one which brings tangible benefits to society.
Therefore, we strive to bring the promise of tissue regeneration into reality by transforming our RGTA® expertise into efficient, safe and widely adopted solutions.
Our roots
As a French biotech company, we are developing products for tissue regeneration utilizing matrix therapy to improve the life of patients who suffer dermatological or neurological disorders.
Our history
OTR3 was founded by two well-known biologists: Pr. Denis Barritault and Pr. Jean-Pierre Caruelle.
Thanks to their pioneering work on growth factors (FGF, HARP/PTN discovery) and medical and industrial long-term vision, they invented and patented the RGTA® or ReGeneraTing Agents technology, a new therapeutic class based on heparan sulfate mimetics.
Our executive committee
OTR3’s executive committee is constituted of members with rich and complementary experiences including academic and medical backgrounds in both pharmaceutical and cosmetic industries.
Steering committee
Our steering committee, consisting of renowned professionals, advices OTR3’s team on scientific, strategic and business issues.
